4//SEC Filing
POON CHRISTINE A 4
Accession 0001189014-25-000005
CIK 0000872589other
Filed
Oct 30, 8:00 PM ET
Accepted
Oct 31, 4:09 PM ET
Size
21.0 KB
Accession
0001189014-25-000005
Insider Transaction Report
Form 4
POON CHRISTINE A
Director
Transactions
- Sale
Common Stock
2025-10-29$654.42/sh−1,915$1,253,214→ 3,552 total - Sale
Common Stock
2025-10-29$655.10/sh−100$65,510→ 3,452 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-29−6,500→ 2,712 totalExercise: $520.01Exp: 2026-01-04→ Common Stock (6,500 underlying) - Exercise/Conversion
Common Stock
2025-10-29$520.01/sh+6,500$3,380,065→ 8,852 total - Sale
Common Stock
2025-10-29$653.50/sh−2,735$1,787,323→ 5,467 total - Sale
Common Stock
2025-10-29$656.50/sh−712$467,428→ 2,740 total - Sale
Common Stock
2025-10-29$657.29/sh−388$255,029→ 2,352 total - Exercise/Conversion
Common Stock
2025-10-30$520.01/sh+2,712$1,410,267→ 5,064 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2025-10-30−2,712→ 0 totalExercise: $520.01Exp: 2026-01-04→ Common Stock (2,712 underlying) - Sale
Common Stock
2025-10-29$652.68/sh−650$424,242→ 8,202 total
Footnotes (7)
- [F1]Represents volume-weighted average price of sales of 650 shares of Company stock on October 29, 2025 at prices ranging from $652.31 to $652.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
- [F2]Represents volume-weighted average price of sales of 2,735 shares of Company stock on October 29, 2025 at prices ranging from $653.05 to $653.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
- [F3]Represents volume-weighted average price of sales of 1,915 shares of Company stock on October 29, 2025 at prices ranging from $654.01 to $654.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
- [F4]Represents volume-weighted average price of sales of 100 shares of Company stock on October 29, 2025 at prices ranging from $655.02 to $655.16. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
- [F5]Represents volume-weighted average price of sales of 712 shares of Company stock on October 29, 2025 at prices ranging from $656.33 to $656.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
- [F6]Represents volume-weighted average price of sales of 388 shares of Company stock on October 29, 2025 at prices ranging from $657.02 to $657.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on October 29, 2025 at each separate price.
- [F7]The stock option vested in three equal annual installments, commencing one year after the date of grant.
Documents
Issuer
REGENERON PHARMACEUTICALS, INC.
CIK 0000872589
Entity typeother
Related Parties
1- filerCIK 0001189014
Filing Metadata
- Form type
- 4
- Filed
- Oct 30, 8:00 PM ET
- Accepted
- Oct 31, 4:09 PM ET
- Size
- 21.0 KB